Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1646
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17769171 | COMPOSITIONS AND METHODS FOR DETECTING PLXDC1 AND PLXDC2 IN HUMAN TISSUES | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18020515 | PLASMA EXCHANGE REMOVAL OF SPD-L1 | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 16964452 | LOW PH PHARMACEUTICAL ANTIBODY FORMULATION | Non-Final OA | AMGEN INC. |
| 19243836 | SUBCUTANEOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF | Final Rejection | argenx BV |
| 18035399 | VISTA AGONIST FOR TREATMENT/PREVENTION OF ISCHEMIC AND/OR REPERFUSION INJURY | Non-Final OA | THE TRUSTEES OF DARTMOUTH COLLEGE |
| 17616246 | BREAST CANCER DETECTION METHODS | Non-Final OA | Cambridge Enterprise Limited |
| 17470722 | METHOD, KIT, AND PROGRAM FOR DETERMINING CHARACTERISTIC OF TUMOR CELL GROUP | Non-Final OA | KABUSHIKI KAISHA TOSHIBA |
| 18461081 | NIDOGEN 1 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET OF HEPATOCELLULAR CARCINOMA, COMPOSITION AND METHODS THEREOF | Non-Final OA | THE UNIVERSITY OF HONG KONG |
| 18216026 | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer | Non-Final OA | Janssen Biotech, Inc. |
| 18300183 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone | Final Rejection | Janssen Biotech, Inc. |
| 17292025 | USE OF CLAZAKIZUMAB TO DESENSITIZE AND IMPROVE RENAL TRANSPLANTATION IN HLA-SENSITIZED PATIENTS | Final Rejection | CEDARS-SINAI MEDICAL CENTER |
| 17757881 | T CELL PERFORMANCE ASSAY AS A PROGNOSTIC FACTOR FOR CLINICAL OUTCOME | Final Rejection | Baylor College of Medicine |
| 17638607 | COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION | Non-Final OA | VOR BIOPHARMA INC. |
| 18280981 | USE OF OREGOVOMAB AND BEVACIZUMAB, PACLITAXEL, CARBOPLATIN FOR TREATMENT OF BRCA-WILD TYPE PLATINUM SENSITIVE RECURRENT | Non-Final OA | CANARIABIO INC. |
| 18349562 | Engineered EpCam Binding Antibodies | Non-Final OA | TigaTX |
| 18260556 | ROR1 BINDING PROTEIN AND USE THEREOF | Non-Final OA | KLUS PHARMA INC. |
| 17271491 | NEOANTIGEN ENGINEERING USING SPLICE MODULATING COMPOUNDS | Non-Final OA | Roche Innovation Center Copenhagen A/S |
| 18144930 | Methods and Compositions for Treating Aging-Associated Impairments with TIMP-2 Recombinant Proteins | Non-Final OA | Grifols Diagnostic Solutions Inc. |
| 18314438 | MODULATION OF BETA CELL REGENERATION THROUGH GPR75 SIGNALING | Final Rejection | New York Medical College |
| 18311991 | METHODS FOR TREATING OR PREVENTING HEADACHE DISORDERS | Non-Final OA | UNITED STATES GOVERNMENT |
| 17909310 | ANTI-CCR8 AGENTS | Non-Final OA | Memorial Sloan Kettering Cancer Center |
| 17675083 | APPLICATION OF NAT1 GENE AS SCREENING MARKER IN GENETIC TRANSFORMATION OF OOMYCETE | Final Rejection | Shandong Agricultural University |
| 17905521 | Interferon Signaling Pathway-Related Gene Panel, Diagnostic Product and Application Thereof | Non-Final OA | Shanghai Precision Medicine Co., Ltd. |
| 17779002 | METHODS OF TREATING CANCER USING DKK-1 INHIBITORS | Non-Final OA | Leap Therapeutics, Inc. |
| 17766726 | COMBINATION THERAPY FOR CANCERS WITH KRAS MUTATION | Non-Final OA | COTHERA BIOSCIENCE, INC. |
| 17627817 | Genetically Engineered Bacteriophage | Final Rejection | Cytophage Technologies |
| 17517567 | USE OF ISATUXIMAB FOR THE TREATMENT OF MULTIPLE MYELOMA | Non-Final OA | Sanofi-Aventis U.S. LLC |
| 17310992 | GRP78 AND/OR HSP70 INHIBITORS FOR THERAPEUTIC USE | Non-Final OA | GHP SCIENTIFIC LIMITED |
| 17198029 | ENHANCED DELIVERY OF DRUGS TO THE BRAIN | Non-Final OA | Nascent Biotech, Inc. |
| 17011239 | VACCINE FOR TREATMENT OF CANCER AND METHOD OF MAKING BY STRESS REPROGRAMMING | Final Rejection | VCell Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy